Severe asthma clinical remission after biologic treatment with anti-IL4/ IL13: A real-life experience

Introduction: Dupilumab, a fully human anti-interleukin-4/interleukin-13 monoclonal antibody, has shown efficacy in many aspects of Type-2 severe asthma management. Currently, we lack real-life studies addressing the achievment of clinical remission in patients treated with this biologic. Materials and methods: We performed a prospective study enrolling 18 patients with severe asthma treated with Dupilumab. We assessed main clinical, functional and biological severe asthma features at baseline (T0) and after a 1-year course of treatment (T12). Clinical remission was defined at T12 in patients without asthma exacerbations, no oral corticosteroid (OCS) use, ACT 20 and FEV1 improvement 100 ml from baseline. Results: Among total population, 38.9% of patients achieved clinical remission at T12. Anti IL-4/IL-13 treatment significantly reduced asthma exacerbations and OCS use in the overall cohort, with a more pronounced ACT improvement in the remission group. Patients achieving clinical remission went through a step down of the inhalation therapy, suspending long-acting anti-muscarinics administration at T12. Conclusions: Treatment with anti-IL4/IL13 can induce clinical remission in patients with T2 severe asthma.

Automated summary

This study found that treatment with Dupilumab can induce clinical remission in patients with severe asthma, with 38.9% of patients achieving remission at the end of the treatment. The treatment also significantly reduced asthma exacerbations and oral corticosteroid use, and improved asthma control in patients.